Get the Stockscreener App
0.5767
5.51%
0.0301
After Hours:
.59
0.0133
+2.31%
Ocugen Inc Stock (OCGN) Latest News
SBI Securities Co. Ltd. Makes New $40,000 Investment in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen, Inc. (NASDAQ:OCGN) Shares Acquired by Rhumbline Advisers - Defense World
Equities Analysts Offer Predictions for Ocugen Q1 Earnings - Defense World
FY2029 Earnings Estimate for Ocugen Issued By HC Wainwright - Defense World
Ocugen’s (OCGN) “Buy” Rating Reiterated at HC Wainwright - Defense World
Ocugen Secures ATMP Classification for Gene Therapies Targeting Vision Loss - MSN
Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates - MSN
Ocugen’s Strategic Advancements and Financial Stability Justify Buy Rating - TipRanks
Ocugen Reports 2024 Financial Results and Advances Gene Therapy Programs - MSN
Attention Long-Term Shareholders of Driven Brands Holdings, - GlobeNewswire
Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); MGP Ingredients, Inc. (NASDAQ: MGPI); and Ocugen, Inc. (NASDAQ: OCGN): Grabar Law Office Investigates Claims on Your Behalf - GlobeNewswire Inc.
Chardan Capital Adjusts Ocugen Price Target to $7 From $6, Maintains Buy Rating -March 06, 2025 at 08:15 am EST - Marketscreener.com
Ocugen, Inc. (NASDAQ:OCGN) Q4 2024 Earnings Call Transcript - Insider Monkey
Ocugen’s Strategic BLA Submissions and Financial Position Support Buy Rating - TipRanks
Beyond The Numbers: 5 Analysts Discuss Ocugen Stock - Benzinga
Ocugen Inc. Navigates Uncertainty Amid Potential Shifts in U.S. Fiscal and Tax Policies - MSN
Y Intercept Hong Kong Ltd Makes New Investment in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen: Q4 Earnings Snapshot - Midland Daily News
Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs - Yahoo Finance
Ocugen Reports Progress in Gene Therapy Trials - TipRanks
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Ocugen Inc Earnings Call: Strategic Gains Amid Financial Challenges - TipRanks
Around the Helix: Cell and Gene Therapy Company Updates – March 5, 2025 - CGTLive™
Ocugen Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Stock Quote & Chart - Ocugen
Ocugen (OCGN) Q4 2024 Earnings Call Transcript - Yahoo
Ocugen’s Geographic Atrophy and Stargardt Gene Therapies Garner Positive ATMP Opinions from EMA - CGTLive™
Earnings call transcript: Ocugen Q4 2024 beats earnings forecast By Investing.com - Investing.com UK
Ocugen to Announce Q4 and Full-Year 2024 Results with Live Webcast on March 5, 2025 - MSN
Ocugen, Inc. SEC 10-K Report - TradingView
Earnings call transcript: Ocugen Q4 2024 beats earnings forecast - Investing.com
Ocugen Inc (OCGN) Q4 Earnings: Revenue Surpasses Estimates at $0 - GuruFocus.com
OCGN Earnings: Ocugen Stock Jumps on Q4 Results & Development Updates - Markets Insider
Ocugen reports Q4 EPS (5c), consensus (5c) - TipRanks
OCUGEN Earnings Results: $OCGN Reports Quarterly Earnings - Nasdaq
Ocugen: Q4 Earnings Snapshot -March 05, 2025 at 07:23 am EST - Marketscreener.com
Ocugen, Inc. Reports Progress on Clinical Trials and FDA Alignment for OCU410ST in Stargardt Disease, Highlights Positive Long-Term Data for OCU400 - Nasdaq
Ocugen stock hits 52-week low at $0.6 amid market challenges - Investing.com
Ocugen Announces Positive Opinion of EMA’s Committee for - GlobeNewswire
Ocugen Announces Positive Opinion Of EMA'S Committee For Advanced Therapies For ATMP Classification - Marketscreener.com
Ocugen announces EC provided position opinion from EMA’s CAT for OCU410 - TipRanks
Ocugen gains EU nod for gene therapy classifications - Investing.com India
Ocugen's Eye Disease Gene Therapies Show 44-52% Slower Lesion Growth After EMA Regulatory Win - StockTitan
Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Methode Electronics, Inc. (NYSE: MEI); and Ocugen, Inc. (NASDAQ: OCGN) - Financial Post
Grabar Law Office is Investigating Claims on Behalf of - GlobeNewswire
UPCOMING OCGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Ocugen, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):